(Q30309168)

16 June 2017

1 reference

title

Pimagedine: a novel therapy for diabetic nephropathy (English)

1 reference

16 June 2017

1 reference

Emaad Abdel-Rahman

1

1 reference

16 June 2017

W Kline Bolton

series ordinal

2

1 reference

16 June 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Expert Opinion on Investigational Drugs

16 June 2017

published in

1 reference

16 June 2017

volume

11

1 reference

16 June 2017

issue

4

1 reference

16 June 2017

page(s)

565-574

1 reference

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

16 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Protein kinase C activation and the development of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Phosphorylation of SLP-76 by the ZAP-70 protein-tyrosine kinase is required for T-cell receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Nutritional and toxicological aspects of the Maillard browning reaction in foods

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Amides are novel protein modifications formed by physiological sugars

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

CGP 48664, a potent and specific S-adenosylmethionine decarboxylase inhibitor: effects on regulation and stability of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Potential therapeutic approaches to the treatment or prevention of diabetic neuropathy: evidence from experimental studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Mechanisms of diabetic vasculopathy: an overview.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Pharmacological treatment strategies in age-related cataracts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Diabetic vascular complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Retardation by Aminoguanidine of Development of Albuminuria, Mesangial Expansion, and Tissue Fluorescence in Streptozocin-Induced Diabetic Rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Renoprotective effects of a novel inhibitor of advanced glycation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

An agent cleaving glucose-derived protein crosslinks in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Breakers of advanced glycation end products restore large artery properties in experimental diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Inhibitors of advanced glycation end product-associated protein cross-linking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Amadorins: novel post-Amadori inhibitors of advanced glycation reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Advanced glycation end products (AGEs)-induced expression of TGF-beta 1 is suppressed by a protease in the tubule cell line LLC-PK1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.4.565

10.1517/13543784.11.4.565

21 January 2018

Identifiers

DOI

1 reference

release_v35o7eis5fhxlmofvpdwq2nnai

16 June 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/v35o7eis5fhxlmofvpdwq2nnai

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference